It is believed that trilostane exerts its effect in advanced breast cancer through three mechanisms: (i) blocking the biosynthesis of estrogen, (ii) direct inhibition of estrogen receptor activity, and (iii) promoting the expression of β-estrogen receptors. The gene discussed is ESR1; the disease is breast carcinoma.